Bivamelagon Phase 2 Win Sets Up Pivotal Trial as Revenue Jumps 80%
RYTM sits 19% above its 52-week low of $74.5 on elevated volume (9.4× avg).
Summary
Rhythm reported positive Phase 2 results for bivamelagon in acquired hypothalamic obesity and plans to start a pivotal Phase 3 trial by end-2026, with first dosing expected in January. That is the new piece of information here; the Q3 numbers and Japan launch were already out. Q3 revenue came in at $92.1 million, up 80% year over year, with a net loss of $42.4 million, or $0.61 per share, and $320.9 million of cash. The bivamelagon program matters because it is an oral MC4R agonist that could broaden the franchise beyond Imcivree, and the Phase 3 start date gives a concrete milestone. Needham kept its Buy rating but cut its price target to $114 from $130.
At the time of this announcement, RYTM was trading at $88.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.